MARKET

INCY

INCY

Incyte Corp
NASDAQ
98.84
-1.21
-1.21%
After Hours: 99.49 +0.65 +0.66% 19:53 02/11 EST
OPEN
98.52
PREV CLOSE
100.05
HIGH
99.79
LOW
97.25
VOLUME
1.93M
TURNOVER
--
52 WEEK HIGH
112.29
52 WEEK LOW
53.56
MARKET CAP
19.40B
P/E (TTM)
16.71
1D
5D
1M
3M
1Y
5Y
1D
Incyte Is Maintained at Sector Perform by RBC Capital
Dow Jones · 10h ago
Incyte Price Target Cut to $92.00/Share From $95.00 by RBC Capital
Dow Jones · 10h ago
RBC Capital Maintains Sector Perform on Incyte, Lowers Price Target to $92
Benzinga · 10h ago
Incyte: Why The Market Is Overreacting To A Guidance 'Miss'
Seeking Alpha · 11h ago
Incyte Price Target Raised to $120.00/Share From $119.00 by Stifel
Dow Jones · 12h ago
Incyte Is Maintained at Buy by Stifel
Dow Jones · 12h ago
Stifel Maintains Buy on Incyte, Raises Price Target to $120
Benzinga · 12h ago
Incyte Is Maintained at Equal-Weight by Wells Fargo
Dow Jones · 12h ago
More
About INCY
Incyte Corporation is a biopharmaceutical company, which is focused on the discovery, development, and commercialization of therapeutics. The Company operates in two therapeutic areas. One therapeutic area is Hematology/Oncology, which is comprised of Myeloproliferative Neoplasms and Graft-Versus-Host Disease, as well as solid tumors and hematologic malignancies. Its other therapeutic area is Inflammation and Autoimmunity, which includes its Dermatology commercial franchise. Its hematology and oncology franchise are comprised of six products, which are JAKAFI (ruxolitinib), MONJUVI (tafasitamab-cxix)/MINJUVI (tafasitamab), PEMAZYRE (pemigatinib), ICLUSIG (ponatinib), NIKTIMVO (axatilimab-csfr), and ZYNYZ (retifanlimab-dlwr), as well as numerous clinical development programs. The Company's pipeline also includes two first-in-class small molecule antagonist of Mas-related G protein-coupled receptor (MRGPRX2) and INCB000547, an oral MRGPRX4 antagonist.

Webull offers Incyte Corp stock information, including NASDAQ: INCY real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, INCY stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading INCY stock methods without spending real money on the virtual paper trading platform.